接受化疗、免疫治疗或化疗免疫治疗的实体瘤患者接种mRNA-1273 COVID-19疫苗:一项前瞻性、多中心、非劣效性试验
VOICE试验在荷兰三个中心前瞻性纳入791名参与者,比较无癌对照组与接受免疫治疗、化疗或化疗免疫治疗的实体瘤患者接种两剂mRNA-1273(100 μg,间隔28天)后的SARS-CoV-2结合抗体应答。各患者队列抗体应答率均非劣于对照组,未观察到新的安全性信号,疫苗相关严重不良事件罕见。
要点
- 实体瘤患者接受化疗、免疫治疗或化疗免疫治疗时,两剂mRNA-1273的抗体应答非劣于无癌对照。
- 各队列SARS-CoV-2结合抗体应答率:对照组100%、免疫治疗组99%、化疗组97%、化疗免疫治疗组100%。
- 3级或更差严重不良事件罕见,无疫苗相关死亡;少数应答不足者或可从第三剂中获益。
核心结论
- 大多数接受化疗、免疫治疗或两者联合治疗的实体瘤患者对mRNA-1273 COVID-19疫苗产生足够的抗体应答,且疫苗在这些患者中安全。
- 少数接种两剂后应答不足的患者可能从第三剂接种中获益。
研究设计与样本
- 前瞻性、多中心、非劣效性试验,在荷兰三个中心开展。
- 纳入18岁及以上、预期寿命超过12个月者,分为四个队列:无癌对照组(队列A)、接受免疫治疗的实体瘤患者(队列B)、接受化疗者(队列C)、接受化疗免疫治疗者(队列D)。
- 参与者间隔28天接受两剂mRNA-1273疫苗,每剂100 μg/0.5 mL肌肉注射。
- 主要终点按方案分析(排除基线样本阳性[>10 BAU/mL]者),定义为第二剂后28天SARS-CoV-2刺突S1特异性IgG血清抗体应答(即SARS-CoV-2结合抗体浓度>10 BAU/mL),非劣效界值为10%。
- 2021年2月17日至3月12日共纳入791名参与者,中位随访122天(IQR 118至128)。
主要发现
- 队列A可评估240例中240例(100%;95% CI 98至100)出现SARS-CoV-2结合抗体应答,队列B为131例中130例(99%;96至>99),队列C为229例中223例(97%;94至99),队列D为143例中143例(100%;97至100)。
- 各患者队列的SARS-CoV-2结合抗体应答均非劣于队列A。
- 未观察到新的安全性信号。
- 3级或更差严重不良事件:队列A无,队列B为137例中3例(2%),队列C为244例中6例(2%),队列D为163例中1例(1%);其中4起事件(发热2起,腹泻和发热性中性粒细胞减少各1起)可能与接种相关。
- 无疫苗相关死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with cancer have an increased risk of complications from SARS-CoV-2 infection. Vaccination to prevent COVID-19 is recommended, but data on the immunogenicity and safety of COVID-19 vaccines for patients with solid tumours receiving systemic cancer treatment are scarce. Therefore, we aimed to assess the impact of immunotherapy, chemotherapy, and chemoimmunotherapy on the immunogenicity and safety of the mRNA-1273 (Moderna Biotech, Madrid, Spain) COVID-19 vaccine as part of the Vaccination Against COVID in Cancer (VOICE) trial. METHODS: This prospective, multicentre, non-inferiority trial was done across three centres in the Netherlands. Individuals aged 18 years or older with a life expectancy of more than 12 months were enrolled into four cohorts: individuals without cancer (cohort A [control cohort]), and patients with solid tumours, regardless of stage and histology, treated with immunotherapy (cohort B), chemotherapy (cohort C), or chemoimmunotherapy (cohort D). Participants received two mRNA-1273 vaccinations of 100 μg in 0·5 mL intramuscularly, 28 days apart. The primary endpoint, analysed per protocol (excluding patients with a positive baseline sample [>10 binding antibody units (BAU)/mL], indicating previous SARS-CoV-2 infection), was defined as the SARS-CoV-2 spike S1-specific IgG serum antibody response (ie, SARS-CoV-2-binding antibody concentration of >10 BAU/mL) 28 days after the second vaccination. For the primary endpoint analysis, a non-inferiority design with a margin of 10% was used. We also assessed adverse events in all patients who received at least one vaccination, and recorded solicited adverse events in participants who received at least one vaccination but excluding those who already had seroconversion (>10 BAU/mL) at baseline. This study is ongoing and is registered with ClinicalTrials.gov, NCT04715438. FINDINGS: Between Feb 17 and March 12, 2021, 791 participants were enrolled and followed up for a median of 122 days (IQR 118 to 128). A SARS-CoV-2-binding antibody response was found in 240 (100%; 95% CI 98 to 100) of 240 evaluable participants in cohort A, 130 (99%; 96 to >99) of 131 evaluable patients in cohort B, 223 (97%; 94 to 99) of 229 evaluable patients in cohort C, and 143 (100%; 97 to 100) of 143 evaluable patients in cohort D. The SARS-CoV-2-binding antibody response in each patient cohort was non-inferior compared with cohort A. No new safety signals were observed. Grade 3 or worse serious adverse events occurred in no participants in cohort A, three (2%) of 137 patients in cohort B, six (2%) of 244 patients in cohort C, and one (1%) of 163 patients in cohort D, with four events (two of fever, and one each of diarrhoea and febrile neutropenia) potentially related to the vaccination. There were no vaccine-related deaths. INTERPRETATION: Most patients with cancer develop, while receiving chemotherapy, immunotherapy, or both for a solid tumour, an adequate antibody response to vaccination with the mRNA-1273 COVID-19 vaccine. The vaccine is also safe in these patients. The minority of patients with an inadequate response after two vaccinations might benefit from a third vaccination. FUNDING: ZonMw, The Netherlands Organisation for Health Research and Development.
引用
- Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021. PMID: 34767759. doi:10.1016/S1470-2045(21)00574-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。